1192172-68-1 Usage
General Description
Ethyl 5-bromo-4-methylbenzofuran-2-carboxylate is a chemical compound used in organic synthesis and drug development. It is a derivative of benzofuran, which is a heterocyclic compound with potential pharmacological properties. This specific derivative has a bromine atom attached to the benzofuran ring, as well as an ethyl ester group and a methyl group. Its structure makes it a useful building block for the synthesis of various pharmaceuticals and bioactive molecules. Ethyl 5-broMo-4-Methylbenzofuran-2-carboxylate has been studied for its potential as an anticancer and antiviral agent, as well as for its activity in the central nervous system. Due to its diverse range of biological activities, ethyl 5-bromo-4-methylbenzofuran-2-carboxylate is a valuable compound in medicinal chemistry and drug discovery research.
Check Digit Verification of cas no
The CAS Registry Mumber 1192172-68-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,9,2,1,7 and 2 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1192172-68:
(9*1)+(8*1)+(7*9)+(6*2)+(5*1)+(4*7)+(3*2)+(2*6)+(1*8)=151
151 % 10 = 1
So 1192172-68-1 is a valid CAS Registry Number.
1192172-68-1Relevant articles and documents
FXR receptor agonist
-
, (2019/02/10)
The present invention discloses an FXR receptor agonist, belongs to the technical field of medicine, and particularly relates to a compound represented by a formula (I), a pharmaceutically acceptablesalt, an ester or a stereoisomer thereof, wherein R, R, R, M, L, L1, W, A , B, Q, m and n are defined in the specification. The present invention further relates to a preparation method of the compound, a pharmaceutical preparation, and applications in preparation of drugs for treatment and/or prevention of nonalcoholic fatty liver disease, primary biliary cirrhosis, lipid metabolism disorder, diabetic complication, malignant tumors and other related diseases mediated by FXR receptors. The formula I is defined in the specification.
